Macitentan 10 mg: Clinical Trials

7 trials of Macitentan 10 mg, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 3 terminated, 1 active not recruiting. 7 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 37Completed 3, Terminated 3, Active not recruiting 1

Follow Macitentan 10 mg: new trials by email Literature Review of Macitentan 10 mg trials Research Report on Macitentan 10 mg

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg - Pulmonary Arterial Hypertension
Phase 3Active not recruitingActelion9352020-06-302026-11-03
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg - Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Phase 3CompletedActelion1872019-07-292025-12-19
An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.
macitentan 10 mg - Congenital Heart Disease With Fontan Circulation
Phase 3TerminatedActelion1122019-04-112023-03-07
A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
macitentan 10 mg - Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Phase 3TerminatedActelion92019-01-082021-06-18
Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects
Macitentan 10 mg, Placebo - Congenital Heart Disease
Phase 3CompletedActelion1422017-08-142025-03-30
Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
Macitentan 10 mg, Placebo - Pulmonary Arterial Hypertension
Phase 3CompletedActelion2262013-05-212018-02-23
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Macitentan 3 mg, Macitentan 10 mg, Placebo - Digital Ulcers
Phase 3TerminatedActelion2652011-12-012025-02-04

Conditions studied

Pulmonary Arterial Hypertension (3)  ·  Eisenmenger Complex (1)  ·  Heart Defects, Congenital (1)  ·  Scleroderma, Systemic (1)  ·  Univentricular Heart (1)  ·  digital ulcers (1)

Sponsors

Actelion (7)

Countries

China (5)  ·  Poland (5)  ·  United States (5)  ·  Australia (4)  ·  Canada (4)  ·  Czechia (4)  ·  France (4)  ·  Germany (4)  ·  Taiwan (4)  ·  United Kingdom (4)  ·  Bulgaria (3)  ·  Denmark (3)  ·  Japan (3)  ·  Malaysia (3)  ·  Mexico (3)

Top investigators

Hany Rofael, MD (1)  ·  Thierry Francis Briand, MD (1)  ·  Yoshinari Yokoyama, PhD (1)

Results publications

PMID 27163986, PMID 30586694, PMID 38267108, PMID 41250682, PMID 41820779, PMID 42023995

NIH funding

2014 (1), 2016 (1), 2018 (1), 2019 (1)